BIOMAT Database Logo BIOMAT Database Logo

Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. 1985

R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono

The adequacy, selectivity and long-term persistence of inhibition in cyclooxygenase-dependent platelet function by a daily low-dose (0.45 mg kg-1 day-1) aspirin treatment have been evaluated in 15 patients after a recent (less than 17 days) acute myocardial infarction. Serum thromboxane (TX) B2, an index of platelet TXA2 production, was decreased by 94-98% (P less than 0.001) by aspirin, while urinary excretion of 6-keto-prostaglandin F1 alpha, as an index of extraplatelet cyclooxygenase activity, remained unchanged. Compared to placebo, aspirin induced a persistent increase in bleeding time (% difference 45.6 +/- 21.4, mean +/- SD) and a decrease in platelet aggregation by ADP, epinephrine, collagen and arachidonic acid. No tendency towards an attenuation of the effects was apparent for the period of aspirin administration (4 weeks). Aspirin 0.45 mg kg-1 day-1 is adequate and selective in the long-term inhibition of TX-related platelet function in patients after acute myocardial infarction. The clinical effectiveness of such a regimen remains to be proven in clinical trials.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011451 Prostaglandin-Endoperoxide Synthases Enzyme complexes that catalyze the formation of PROSTAGLANDINS from the appropriate unsaturated FATTY ACIDS, molecular OXYGEN, and a reduced acceptor. Fatty Acid Cyclo-Oxygenase,PGH Synthase,Prostaglandin H Synthase,Prostaglandin Synthase,Prostaglandin-Endoperoxide Synthase,Arachidonic Acid Cyclooxygenase,Cyclo-Oxygenase,Cyclooxygenase,Cyclooxygenases,Hydroperoxide Cyclase,PGH2 Synthetase,Prostaglandin Cyclo-Oxygenase,Prostaglandin Cyclooxygenase,Prostaglandin Endoperoxide Synthetase,Prostaglandin G-H Synthase,Prostaglandin H2 Synthetase,Prostaglandin Synthetase,Cyclase, Hydroperoxide,Cyclo Oxygenase,Cyclo-Oxygenase, Fatty Acid,Cyclo-Oxygenase, Prostaglandin,Cyclooxygenase, Arachidonic Acid,Cyclooxygenase, Prostaglandin,Endoperoxide Synthetase, Prostaglandin,Fatty Acid Cyclo Oxygenase,G-H Synthase, Prostaglandin,Prostaglandin Cyclo Oxygenase,Prostaglandin Endoperoxide Synthases,Prostaglandin G H Synthase,Synthase, PGH,Synthase, Prostaglandin,Synthase, Prostaglandin G-H,Synthase, Prostaglandin H,Synthase, Prostaglandin-Endoperoxide,Synthases, Prostaglandin-Endoperoxide,Synthetase, PGH2,Synthetase, Prostaglandin,Synthetase, Prostaglandin Endoperoxide,Synthetase, Prostaglandin H2
D001760 Bleeding Time Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function. Aspirin Tolerance Test,Bleeding Time, Template,Duke Method,Ivy Method,Template Bleeding Time,Aspirin Tolerance Tests,Bleeding Times,Bleeding Times, Template,Method, Duke,Method, Ivy,Template Bleeding Times,Test, Aspirin Tolerance,Tests, Aspirin Tolerance,Time, Bleeding,Time, Template Bleeding,Times, Bleeding,Times, Template Bleeding,Tolerance Test, Aspirin,Tolerance Tests, Aspirin
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.
June 1982, The Journal of clinical investigation,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.
January 1981, The New England journal of medicine,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
[The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction].
August 1993, Zhonghua nei ke za zhi,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man.
May 1993, Clinical science (London, England : 1979),
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction (AMI).
October 1995, Chinese medical journal,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Low dose aspirin: selective inhibition of rectal dialysis thromboxane B2 in healthy volunteers.
October 1994, Alimentary pharmacology & therapeutics,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Selective inhibition of platelet cyclooxygenase with controlled release, low-dose aspirin.
October 1990, Australian and New Zealand journal of medicine,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.
April 2022, Clinical pharmacology and therapeutics,
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis.
May 1981, Lancet (London, England),
R De Caterina, and D Giannessi, and W Bernini, and P Gazzetti, and C Michelassi, and A L'Abbate, and L Donato, and P Patrignani, and P Filabozzi, and C Patrono
Low dose aspirin and secondary myocardial infarction.
September 1996, Israel journal of medical sciences,
Copied contents to your clipboard!